How worthwhile is methylene blue as a treatment of malaria?

References

• White N, Pukrittayakamee S, Hien TT, et al. Malaria. Seminar. Lancet. 2014;383:723–735.
   PubMed Web of Science ®Google Scholar
• Müller O. Malaria in Africa: challenges for control and elimination in the 21st Century. Frankfurt: Peter Lang Verlag; 2011.
   Google Scholar
• WHO. World Malaria report 2018. Geneva 2018.
   Google Scholar
• Ashley EA, Pyae Phyo A, Woodrow CJ. Malaria. Lancet. 2018;391(10130):1608–1621.
   PubMed Web of Science ®Google Scholar
• Müller O, Lu G, von Seidlein L. Geographic expansion of artemisinin resistance. Journal of Travel Medicine. 2019 1;26(4).
   Google Scholar
• Müller O, Sie A, Meissner P, et al. Artemisinin resistance on the Thai-Cambodian border. Lancet. 2009;374(9699):1419.
   PubMedGoogle Scholar
• Shanks GD, Edstein MD, Jacobus D. Evolution from double to triple-antimalarial drug combinations. Trans R Soc Trop Med Hyg. 2015;109(3):182–188.
   PubMed Web of Science ®Google Scholar
• Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis. 2010;10(10):673–681.
   PubMed Web of Science ®Google Scholar
• Recht J, Ashley E, White N. Safety of 8-aminoquinoline antimalarial medicines. Geneva, Switzerland: WHO; 2014.
   Google Scholar
• Schirmer RH, Coulibaly B, Stich A, et al. Methylene blue as an antimalarial agent. Redox Rep. 2003;8(5):272–275.
   PubMed Web of Science ®Google Scholar
• Schirmer RH, Adler H, Pickhardt M, et al. Lest we forget you–methylene blue … . Neurobiol Aging. 2011;32(12):2325e7–16.
   Web of Science ®Google Scholar
• Walter-Sack I, Rengelshausen J, Oberwittler H, et al. High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol. 2009;65(2):179–189.
   PubMed Web of Science ®Google Scholar
• DiSanto AR, Wagner JG. Pharmacokinetics of highly ionized drugs. II. Methylene blue–absorption, metabolism, and excretion in man and dog after oral administration. J Pharm Sci. 1972;61(7):1086–1090.
   PubMed Web of Science ®Google Scholar
• Peter C, Hongwan D, Kupfer A, et al. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000;56(3):247–250.
   PubMed Web of Science ®Google Scholar
• Orth K, Ruck A, Stanescu A, et al. Intraluminal treatment of inoperable oesophageal tumours by intralesional photodynamic therapy with methylene blue. Lancet. 1995;345(8948):519–520.
   PubMed Web of Science ®Google Scholar
• Mansouri A, Lurie AA. Concise review: methemoglobinemia. Am J Hematol. 1993;42(1):7–12.
   PubMed Web of Science ®Google Scholar
• Juffermans NP, Vervloet MG, Daemen-Gubbels CRG, et al. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide-Biol Ch. 2010;22(4):275–280.
   PubMed Web of Science ®Google Scholar
• Zulian GB, Tullen E, Maton B. Methylene blue for ifosfamide-associated encephalopathy. N Engl J Med. 1995;332(18):1239–1240.
   PubMed Web of Science ®Google Scholar
• Van der Horst C, Stuebinger H, Seif C, et al. Priapism - etiology, pathophysiology and management. Int Braz J Urol. 2003;29(5):391–400.
   PubMedGoogle Scholar
• Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion. 2003;43(9):1322–1329.
   PubMed Web of Science ®Google Scholar
• Guttmann P, Ehrlich P. Über die Wirkung des Methylenblau bei malaria. Berliner Klin Wochenschr. 1891;28:935–956.
   Google Scholar
• Lu G, Nagbanshi M, Goldau N, et al. Efficacy and safety of methylene blue in the treatment of malaria: a systematic review. BMC Med. 2018;16:59.
   PubMed Web of Science ®Google Scholar
• Ohrt C, Li Q, Obaldia N, et al. Efficacy of intravenous methylene blue, intravenous artesunate, and their combination in preclinical models of malaria. Malar J. 2014;13:415.
   PubMed Web of Science ®Google Scholar
• Pascual A, Henry M, Briolant S, et al. In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs. Antimicrob Agents Chemother. 2011;55(5):2472–2474.
   PubMed Web of Science ®Google Scholar
• Wirjanata G, Sebayang BF, Chalfein F, et al. Potent Ex vivo activity of naphthoquine and methylene blue against drug-resistant clinical isolates of plasmodium falciparum and plasmodium vivax. Antimicrob Agents Chemother. 2015;59(10):6117–6124.
   PubMed Web of Science ®Google Scholar
• Akoachere M, Buchholz K, Fischer E, et al. In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisinins. Antimicrob Agents Chemother. 2005;49(11):4592–7.
   PubMed Web of Science ®Google Scholar
• Adjalley SH, Johnston GL, Li T, et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc Natl Acad Sci U S A. 2011;108(47):E1214–23.
   PubMed Web of Science ®Google Scholar
• Garavito G, Bertani S, Rincon J, et al. Blood schizontocidal activity of methylene blue in combination with antimalarials against Plasmodium falciparum. Parasite. 2007;14(2):135–140.
   PubMedGoogle Scholar
• Bountogo M, Zoungrana A, Coulibaly B, et al. Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Tropical Med Int Health. 2010;15(6):713–717.
   PubMed Web of Science ®Google Scholar
• Coulibaly B, Zoungrana A, Mockenhaupt FP, et al. Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS One. 2009;4(5):e5318.
   PubMed Web of Science ®Google Scholar
• Coulibaly B, Pritsch M, Bountogo M, et al. Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomised controlled trial in Burkina Faso. J Infect Dis. 2015;211(5):689–697.
   PubMed Web of Science ®Google Scholar
• Müller O, Mockenhaupt FP, Marks B. et al. Haemolysis risk in methylene blue treatment of G6PD-sufficient and G6PD-deficient West-African children with uncomplicated falciparum malaria: a synopsis of four RCTs. Pharmacoepidem Dr S. 2013;22(4):376–385.
   PubMed Web of Science ®Google Scholar
• Dicko A, Roh ME, Diawara H, et al. Phase 2, single-blind randomised controlled trial of the efficacy and safety of primaquine and methylene blue for preventing Plasmodium falciparum transmission in Mali. Lancet Infect Dis. 2018;18(6):627–639.
   PubMedGoogle Scholar